Analysis of the expression of cytokines and chemokines, platelet‐leukocyte aggregates, sCD40L and sCD62P in cutaneous melanoma

Abstract

AbstractBackgroundCutaneous melanoma (CM) is a malignancy with a variable incidence worldwide and a poor advanced‐stage prognosis. Melanoma growth is closely associated with the immune system.MethodsA cross‐sectional study was performed on CM patients admitted at the Hospital de Cancer de Pernambuco (HCP) between 2015 and 2018. Fifty‐one CM patients were included, and 30 healthy individuals. The study aimed to evaluate the association of platelet activation mechanisms and inflammatory response in patients with cutaneous melanoma.ResultsElevated serum IL10 and low serum TNF levels in CM patients compared to controls (p < 0.05). High IL6 levels in patients with negative lymph nodes LN (−) compared to positive lymph nodes group (LN +, p = 0.0005). Low RANTES levels in patients compared to controls (p < 0.05). Elevated levels of platelet‐lymphocyte (PLA), platelet‐monocytes (PMA), and platelet‐neutrophils (PNA) aggregates were observed in patients compared to controls (p < 0.05). CM patients with stage II had lower PMA levels than stages I and III (p < 0.05). High PMA levels were observed in patients with LN (+) compared to the LN (‐) group (p < 0.0001). Patients with SSM had high levels of sCD40L and sCD62P compared to controls (p < 0.05)). High sCD40L levels in stage II compared to the stage III group, and sCD62P in stages I and II compared to the stage III group (p < 0.05). High sCD62P levels in patients with LN (‐) compared to the group LN (+) (p < 0.05).ConclusionIt was observed the immunosuppressive profile in CM may favor tumor progression. High levels of platelet‐leukocyte aggregates, sCD40L, and sCD62P may be associated with the worst prognosis.